deltatrials
Completed PHASE3 INTERVENTIONAL 5-arm NCT03535194

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2

Sponsor: Eli Lilly and Company

Conditions Psoriasis
Interventions Mirikizumab Placebo Secukinumab
Updated 30 times since 2018 Last updated: Mar 3, 2021 Started: Jun 26, 2018 Primary completion: Mar 5, 2020 Completion: Jun 3, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Psoriasis and is currently completed. Eli Lilly and Company leads this study, which shows 30 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jul 2024 · 39 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

30 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Apr 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE3

▶ Show 25 earlier versions

  1. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jul 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  3. May 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  10. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  11. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Aug 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  13. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  14. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  15. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  16. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  17. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  18. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  19. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  20. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  21. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  22. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  23. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  24. Jul 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE3

  25. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Afula, Israel , Andover, United States , Asahikawa, Japan , Bad Bentheim, Germany , Bakersfield, United States , Barcelona, Spain , Baton Rouge, United States , Bayamón, Puerto Rico , Beersheba, Israel and 146 more locations